发明名称 USING EP4 RECEPTOR ANTAGONISTS IN TREATING IL-23-MEDIATED DISEASES
摘要 FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound with EP4 receptor antagonist activity or its pharmaceutically acceptable salt, which is effective in treating an immune disease or allergy. This invention also refers to a compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt with EP4 receptor antagonist activity, which is effective in treating an immune disease or allergy. This invention also refers to a pharmaceutical composition for treating an immune disease or allergy, which contains a therapeutically effective amount of the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt.EFFECT: invention refers to a method of treating an immune disease of allergy in an animal subject, including a mammal subject, which involves administering the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt into the animal subject.9 cl, 3 dwg, 3 ex
申请公布号 RU2571816(C2) 申请公布日期 2015.12.20
申请号 RU20120140450 申请日期 2011.02.22
申请人 RAKVALIA FARMA INK. 发明人 KANAZAVA KIJOSI;NONOMURA KADZUKHIKO;OKUMURA TAKAKO;KOIDZUMI SINITI
分类号 A61K45/00;A61K31/38;A61K31/4184;A61K31/44;A61K31/64;A61P29/00;A61P31/08 主分类号 A61K45/00
代理机构 代理人
主权项
地址